Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2003-02-25
2008-10-28
Lankford, L B (Department: 1651)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
C424S093700, C435S325000, C435S395000, C435S400000, C604S004010, C604S005020, C604S006010, C604S006040, C623S023650
Reexamination Certificate
active
07442546
ABSTRACT:
A method of immunomodulation by contacting the bodily fluid of a patient with renal tubule cells outside of the kidney.
REFERENCES:
patent: 3734851 (1973-05-01), Matsumura
patent: 4242460 (1980-12-01), Chick et al.
patent: 4354933 (1982-10-01), Lester
patent: 4973493 (1990-11-01), Guire
patent: 5002582 (1991-03-01), Guire et al.
patent: 5360790 (1994-11-01), Humes
patent: 5414075 (1995-05-01), Swan et al.
patent: 5429938 (1995-07-01), Humes
patent: 5437994 (1995-08-01), Emerson et al.
patent: 5459069 (1995-10-01), Palsson et al.
patent: 5499976 (1996-03-01), Dalton
patent: 5516680 (1996-05-01), Naughton et al.
patent: 5549674 (1996-08-01), Humes et al.
patent: 5550050 (1996-08-01), Holland et al.
patent: 5580697 (1996-12-01), Keana et al.
patent: 5605822 (1997-02-01), Emerson et al.
patent: 5639275 (1997-06-01), Baetge et al.
patent: 5653975 (1997-08-01), Baetge et al.
patent: 5656481 (1997-08-01), Baetge et al.
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5676943 (1997-10-01), Baetge et al.
patent: 5686289 (1997-11-01), Humes et al.
patent: 5733727 (1998-03-01), Field
patent: 5763266 (1998-06-01), Palsson et al.
patent: 5773286 (1998-06-01), Dionne et al.
patent: 5795790 (1998-08-01), Schinstine et al.
patent: 5833978 (1998-11-01), Tremblay
patent: 5843781 (1998-12-01), Ballerman et al.
patent: 5858653 (1999-01-01), Duran et al.
patent: 5906817 (1999-05-01), Moullier et al.
patent: 5919449 (1999-07-01), Dinsmore
patent: 5965125 (1999-10-01), Mineau-Hanschke
patent: 6060270 (2000-05-01), Humes
patent: 6110209 (2000-08-01), Stone
patent: 6150164 (2000-11-01), Humes
patent: 6156304 (2000-12-01), Glorioso et al.
patent: 6653131 (2003-11-01), Humes
patent: 1 479 002 (1974-06-01), None
patent: WO 89/01967 (1989-03-01), None
patent: WO 91/00119 (1991-01-01), None
patent: WO 92/07615 (1992-05-01), None
patent: WO 93/17696 (1996-09-01), None
H. Humes, et al., “Replacement of Renal Function in Uremic Animals with a Tissue-Engineered Kidney”, Nature Biotechnology, vol. 17, pp. 451-455, 1999.
R. Bone, “Systemic Inflammatory Response Syndrome: A Unifying Concept of Systemic Inflammation”, Sepsis and Multiorgan Failure, 1997, pp. 3-10.
H. Humes, et al., “Tissue Engineering of a Bioartificial Renal Tubule Assist Device: In Vitro Transport and Metabolic Characteristics”, Kidney International, vol. 55, 1999, pp. 2502-2514.
H. Humes, “Bioartificial Kidney for Full Renal Replacement Therapy”, Seminars in Nephrology, vol. 20, No. 1, Jan. 2000, pp. 71-82.
J. Walker, et al., “The Language of Biotechnolgy”, 1988, p. 126.
R. Freshney, “Culture of Animal Cells”, A Manual of Basic Technique, 2ndEd., 1987, pp. 1-13 and 197-206.
S. MacKay et al., “Tissue Engineering of a Bioartificial Renal Tubule”, ASAIO Journal, vol. 44, No. 3, May-Jun. 1998, pp. 179-183.
S. Pobojewski, “U Researchers Unveil Component of Bio-Artificial Kidney”, The University Record, May 24, 1999.
C. Natanson, et al., “Role of Endotoxemia in Cardiovascular Dysfunction and Mortality”, The Journal of Clinical Investigation, Inc., vol. 83, Jan. 1989, pp. 243-251.
B. Freeman, et al., “Continuous Arteriovenous Hemofiltration Does Not Improve Survival in a Canine Model of Septic Shock”, Journal of the American College of Surgeons, Mar. 1995, vol. 180, pp. 286-291.
J. Kellum, “Immunomodulation In Sepsis: The Role of Hemofiltration”, Minerva Anestesiologica, vol. 65, No. 6, pp. 410-418.
G. Bernard, M.D., et al., “Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis”, The New England Journal of Medicine, vol. 344, No. 10, Mar. 8, 2001, pp. 699-709.
D. Tran et al., “Age, Chronic Disease, Sepsis, Organ System Failure, and Mortality in a Medical Intensive Care Unit”, Critical Care Medicine, vol. 18, No. 5, pp. 474-479, May 1990.
S. Donnelly et al., “Mediators, Mechanisms and Mortality in Major Trauma”, Resuscitation, vol. 28, pp. 87-92, 1994.
R. Bone, M.D., et al., “A Controlled Clinical Trial of High-Dose Methylprednisolone in the Treatment of Severe Sepsis and Septic Shock”, The New England Journal of Medicine, vol. 317, No. 11, pp. 653-658.
K. Horn, “Evolving Strategies in the Treatment of Sepsis and Systemic Inflammatory Response Syndrome (SIRS)”, Q.J. Med, 1998, vol. 91, pp. 265-277.
M. Pinsky, “Serum Cytokine Levels in Human Septic Shock”, Chest, vol. 103, No. 2, Feb. 1993, pp. 565-575.
C. Marty, et al., “Circulating Interleukin-8 Concentration in Patients with Multiple Organ Failure of Septic and Nonseptic Origin”, Critical Care Medicine, vol. 22, No. 4, pp. 673-679, Apr. 1994.
P. Damas, M.D., Ph.D., et al., “Tumor Necrosis Factor and Interleukin-1 Serum levels During Severe Sepsis in Humans”, Critical Care Medicine, vol. 17, No. 10, pp. 975-978, Oct. 1989.
C. Dinarello, “The Proinflammatory Cytokines Interleukin-1 and Tumor Necrosis Factor and Treatment of the Septic Shock Syndrome”, The Journal of Infectious Diseases, 1991: 163, pp. 1177-1184.
T. Calandra, et al., “Prognostic Values of Tumor Necrosis Factor/Cachectin, interleukin-1, Interferon-α, and Interferon-y in the Serum of Patients with Septic Shock”, The Journal of Infectious Diseases, 1990: 161, pp. 982-987.
J. Jiang, et al., “Plasma Cytokines and Endotoxin Levels in Patients with Severe Injury and Their Relationship with Organ Damage”, Injury, vol. 28, No. 8, pp. 509-513, 1997.
D. Breen, et al., “Acute Renal Failure as a Part of Multiple Organ Failure: The Slippery Slope of Critical Illness”, Kidney International, vol. 53, Suppl. 66, 1998, pp. S25-S33.
M. Sarnak, et al., “Mortality Caused by Sepsis in Patients with End-Stage Renal Disease Compared with the General Population”, Kidney International, vol. 58, 2000, pp. 1758-1764.
M. Girndt, et al., “Production in Interleukin-6, Tumor Necrosis Factor α and Interleukin-10 in vitro Correlates with the Clinical Immune Defect in Chronic Hemodialysis Patients”, Kidney International, vol. 47, 1995, pp. 559-565.
M. Girndt, et al., “Impaired Cellular Immune Function in Patients with End-Stage Renal Failure”, Nephrol Dial Transplant, 1999: 14, pp. 2807-2810.
M. Thomas, M.D., Ph.D., et al., “Hyptovitaminosis D in Medical Inpatients”, The New England Journal of Medicine, vol. 338, No. 12, Mar. 19, 1998, pp. 777-783.
A. Trifillis, et al., “Isolation, Culture and Characterization of Human Renal Tubular Cells”, The Journal of Urology, vol. 133, February, pp. 324-329.
C. Detrisac, et al., “Tissue Culture of Human Kidney Epithelial Cells of Proximal Tubule Orgin”, Kidney International, vol. 25, 1984, pp. 383-390.
R. Bone, M.D., “Why Sepsis Trials Fail”, JAMA, Aug. 21, 1996, vol. 276, No. 7, pp. 565-566.
R. Bone, M.D., “Toward a Theory Regarding the Pathogenesis of the Systemic Inflammatory Response Syndrom: What We Do and Do Not Know About Cytokine Regulation”, Crit Care Med., 1996, vol. 24, No. 1, pp. 163-172.
C. Hack, et al., “Interleukin-8 in Sepsis: Relation to Shock and Inflammatory Mediators”, Infection and Immunity, Jul. 1992, vol. 60, No. 7, pp. 2835-2842.
R. Bone, M.D., “Immunologic Dissonance: A Continuing Evolution in Our Understanding of the Systemic Inflammatory Response Syndrome(SIRS) and the Multiple Organ Dysfunction Syndrome (MODS)”, Ann Tern Med., 1996, vol. 125, pp. 680-687.
R. Bone, M.D., “Sepsis: A New Hypothesis for Pathogenesis of the Disease Process”, Chest, vol. 112, No. 1, Jul. 1997, pp. 235-243.
J. Reeves, et al., “Continuous Plasmafiltration in Sepsis Syndrome”, Crit Care Med., vol. 27, No. 10, pp. 2096-2104.
A. De Vriese, et al., “Continuous Renal Replacement Therapies in Sepsis: Where are the Data?”, Nephrol Dial Transplant, 1998, vol. 13, pp. 1362-1364.
J. Vincent, M.D., et al.
Hamilton Brook Smith & Reynolds P.C.
Kim Taeyoon
Lankford L B
The Regents of the University of Michigan
LandOfFree
Method of modulating inflammatory response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of modulating inflammatory response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of modulating inflammatory response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3991659